RE:RE:Money Threat I contend that the "market" has little to do with it, prophetoffact. In my opinion, Bioasis has never issued really good news. Worse, the Bioasis history of announcing collaborations that ended in nothing have caused investor scepticism. That's on Bioasis, not the market.
The list of pharmas and biotechs that have come and gone is greater than the list that Bioasis now has. Vaccinex, MedImmune, Astellas, Shire, the large pharma with GABAa (possibly gone), Prothena, B4B and Scarpa, UCB, and others, several that I cannot mention. We have no updates yet from Chiesi, Aposense, Oxyrane, Daiichi Sankyo, and we are still waiting for something on progranulin. Is somebody working on xB3-001 or not? Bioasis has too many secrets and no number of invitation-only roadshow meetings will reveal the secrets of what is and what is not.
Bioasis looks like a failure because that's what it has been. Founded in 2008. No peptide until 2014. Six years of what? Nothing. Well, Texas Tech, but it wasn't the peptide, it wasn't a fusion protein, and it hasn't yet morphed into a real preclinical or clinical program. Bioasis couldn't pay WuXi, so work with xB3-001 ended. A declining share price restricted financing activity..It all resulted in a false start with a new CEO that ended in 2019 after eleven years of nothing much, including no money and no ability to raise money without massive dilution.
Whatever the issues I have with DrDR, she's the only one to make a plan and work the plan. She has followed the shareholders' dictate to avoid dilutive equity financing. The DrDR plan is ambitious but she has no wiggle room for failure. Bioasis is at the Rubicon.
It's not the market, prophetoffact. Biotech trends don't inform us about everything. Companies are responsible for their own welfare, including navigation through hard times.
So the questions are, will Bioasis produce substantive proof of xB3 fusion protein capability and will deals of substantial value get done. That's it. If BOTH questions are answered in the positive, then my opinion is that the Bioasis share price will take care of itself no matter how the market is trending.
Is Bioasis a competitor to the multibillion-dollar Denali, or is it not? If it is, then the Bioasis share price will start its march toward the Denali valuation, adjusted for RELATIVE capabilities of their technologies and their RELATIVE advancement through clinical programs.
Scientific and commercial accomplishments can drive share price because they have intrinsic value and they predict more value. Market trends do not have such intrinsic value.
jd